Enhancing T cell immunity in a type of cancer called undifferentiated pleomorphic sarcoma.
Targeting Radiation-Induced Myeloid Cells to Promote T cell Immunity in Undifferentiated Pleomorphic Sarcoma
This study is looking at how combining radiation therapy with a new treatment called BO-112 can help boost the immune system's ability to fight undifferentiated pleomorphic sarcoma (UPS), and it will involve both animal tests and patients to see how well this approach works.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project ID | NIH-10983726 on NIH RePORTER |
What this research studies
This research investigates how radiation therapy can be combined with a new treatment called BO-112 to improve the immune response against undifferentiated pleomorphic sarcoma (UPS). The approach focuses on reprogramming myeloid cells, which can suppress the immune system, to instead promote T cell activity against tumors. The research will involve both animal models and patients with UPS to evaluate the effectiveness of this combination therapy in enhancing anti-tumor immunity.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with undifferentiated pleomorphic sarcoma who are undergoing or have undergone radiation therapy.
Not a fit: Patients with other types of cancer or those who do not have undifferentiated pleomorphic sarcoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for patients with undifferentiated pleomorphic sarcoma by enhancing their immune response against the cancer.
How similar studies have performed: Previous research has shown promise in using immune checkpoint blockade in combination with radiation therapy, suggesting that this approach may yield beneficial results.
Where this research is happening
Stanford, United States
- Stanford University — Stanford, United States (Active)
Researchers
- Principal investigator: Kalbasi, Anusha — Stanford University
- Study coordinator: Kalbasi, Anusha
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.